Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 5/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640569 | 0.80 | KCNH2 (0.42) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24574195 | 0.79 | KMT2A (0.37) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1415472 | 0.79 | CCNC (0.51) | NAMPTCHRM1CCNT1CCNB2CCNE2 | |
| SCHEMBL1299318 | 0.78 | KMT2A (0.39) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1299207 | 0.78 | NLRP3 (0.41) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL626824 | 0.78 | CCNC (0.43) | NLRP3NAMPTCHRM1KMT2ACCNT1 | |
| SCHEMBL24574049 | 0.78 | KMT2A (0.36) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL20651818 | 0.77 | NLRP3 (0.38) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL19422051 | 0.77 | BRD4 (0.41) | NLRP3ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL14690634 | 0.77 | CCNC (0.43) | NLRP3NAMPTCHRM1KMT2ACCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 749 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152028-B2 | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-11-26 | — | — | US | claimed |
| EP-4267577-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2023-11-01 | — | — | EP | claimed |
| CN-116867780-A | Process for preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | 科赛普特治疗公司 | 2023-10-10 | — | — | CN | claimed |
| US-20220227753-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2022-07-21 | — | — | US | claimed |
| WO-2022140600-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-06-30 | — | — | WO | claimed |
| WO-2022134033-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-06-30 | — | — | WO | claimed |
| CN-117050075-B | Biaryl ring BET inhibitor and synthetic method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | THE UNIVERSITY OF NOTTINGHAM (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006434-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006435-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006431-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | NLRP3 4839/4885ALDH1A1 2556/4885HSD17B10 841/4885 |
| US-20220227753-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | NLRP3 2282/4885ALDH1A1 3366/4885HSD17B10 277/4885 |
| US-12152028-B2 | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | NLRP3 2282/4885ALDH1A1 3366/4885HSD17B10 277/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | NLRP3 2766/4885ALDH1A1 217/4885HSD17B10 65/4885 |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | CCNA1, CDK4, CCNO | NLRP3 4856/4885ALDH1A1 995/4885HSD17B10 772/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | NLRP3 4498/4885ALDH1A1 1507/4885HSD17B10 69/4885 |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | ITGA2, ITGB2, ITGB1 | NLRP3 3224/4885ALDH1A1 814/4885HSD17B10 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.